Diabetic Macular Edema Treatments

DIABETIC MACULAR EDEMA TREATMENTS
Generic Brand Strength Form Adult Dose
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS
brolucizumab-dbll Beovu 6mg/0.05mL soln for intravitreal inj 6mg (0.05mL) every 6wks (approx. 39–45 days) for the 1st 5 doses, followed by 6mg (0.05mL) once every 8–12wks.
ranibizumab Lucentis 6mg/mL (0.3mg), 10mg/mL (0.5mg) soln for intravitreal inj 0.3mg (0.05mL of 6mg/mL) once a month (approx. 28 days)
Cimerli* 6mg/mL (0.3mg), 10mg/mL (0.5mg) soln for intravitreal inj
VEGF INHIBITOR + ANGIOPOIETIN-2 (ANG-2) INHIBITOR
faricimab-svoa Vabysmo 120mg/mL soln for intravitreal inj Regimen 1: 6mg (0.05mL) once every 4wks for at least 4 doses, then may be adjusted by up to 4-week interval increments or reductions of up to 8-week interval increments based on CST and visual acuity evaluations through week 52; or
Regimen 2: 6mg (0.05mL) once every 4wks for the 1st 6 doses, followed by 6mg (0.05mL) every 8wks over the next 28wks.
VEGF INHIBITOR + HUMAN IgG1
aflibercept Eylea 2mg/0.05mL soln for intravitreal inj 2mg (0.05mL) once every 4wks (approx. 28 days, monthly) for the 1st 5 doses, followed by 2mg (0.05mL) once every 8wks (2mos); some may need the monthly dosing after the 1st 5mos
CORTICOSTEROIDS
dexamethasone Ozurdex 0.7mg intravitreal implant One implant in each affected eye(s)
fluocinolone acetonide Iluvien 0.19mg intravitreal implant One implant in each affected eye(s)
NOTES

* Biosimilar to Lucentis.

† One implant is designed to release fluocinolone at an initial rate of 0.25mcg/day lasting 36mos.

 

Not an inclusive list of medications and/or official indications. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.

Created 10/2022